Claritev (NYSE:CTEV) Posts Quarterly Earnings Results, Beats Expectations By $5.45 EPS

Claritev (NYSE:CTEV) posted its quarterly earnings results on Monday. The company reported $1.77 earnings per share for the quarter, beating analysts’ consensus estimates of ($3.68) by $5.45, FiscalAI reports. The company had revenue of $268.31 million during the quarter.

Here are the key takeaways from Claritev’s conference call:

• Third-quarter revenue rose 9.1% year over year to $268.3 million and Adjusted EBITDA increased 4.4% to $162 million, exceeding expectations. Claritev raised its 2026 revenue, Adjusted EBITDA, and free cash flow guidance.
• Bookings reached $27 million in Q3 and topped $100 million year to date; the company now expects $115 million–$125 million for 2026, up 70%–90% from 2025. More than half of year-to-date bookings came from outside its core payer market, supporting management’s diversification strategy.
• Claims Intelligence grew 17.1%, with NSA dispute initiations up 75% year over year; management expects NSA activity to remain a tailwind. The company also said it expects at least $1.1 billion in revenue in 2027, a year ahead of its prior target.
• Payment & Revenue Integrity remained below plan as clients shifted from legacy clinical negotiations, more than offsetting growth in newer offerings. Management expects the segment to return to growth in 2027, but noted that bookings typically take time to convert to revenue.
• Claritev reported a $25.8 million Q3 free cash flow outflow and ended the quarter with $10.1 million of unrestricted cash, $95 million drawn on its revolver, and net leverage of 7.7x. Management expects a strong Q4 cash-flow rebound and reaffirmed its commitment to deleveraging.

Claritev Stock Up 0.4%

CTEV opened at $24.10 on Tuesday. Claritev has a 52 week low of $11.50 and a 52 week high of $72.67. The stock has a market cap of $408.50 million, a PE ratio of -1.42 and a beta of 1.05. The business’s fifty day simple moving average is $27.15 and its 200 day simple moving average is $25.49.

Insider Activity

In related news, CEO Travis Dalton purchased 4,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 27th. The stock was bought at an average cost of $38.81 per share, with a total value of $174,645.00. Following the completion of the purchase, the chief executive officer directly owned 50,372 shares in the company, valued at approximately $1,954,937.32. This represents a 9.81% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Douglas Garis sold 9,025 shares of Claritev stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $30.59, for a total transaction of $276,074.75. Following the transaction, the chief financial officer directly owned 185,416 shares of the company’s stock, valued at approximately $5,671,875.44. This trade represents a 4.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have bought 77,284 shares of company stock worth $1,927,655 and have sold 23,687 shares worth $769,078. Insiders own 7.40% of the company’s stock.

Key Headlines Impacting Claritev

Here are the key news stories impacting Claritev this week:

• Positive Sentiment: Claritev raised its 2026 revenue outlook to $1.038 billion–$1.043 billion and said it expects at least $1.1 billion in 2027 revenue, citing NSA momentum. The higher outlook points to improved growth prospects. Article: Claritev expects at least $1.1B 2027 revenue, raises 2026 outlook
• Positive Sentiment: Zacks reported a third-quarter loss of $3.64 per share, slightly narrower than the $3.68 loss analysts expected and the $4.07 loss a year earlier. Revenue was $268.31 million. Article: Claritev reports Q3 loss, tops revenue estimates
• Negative Sentiment: Despite the modest improvement against estimates and last year, Claritev remained loss-making on the per-share measure reported by Zacks, a continuing concern for investors. Article: Claritev reports third-quarter 2026 results

Wall Street Analyst Weigh In

Several brokerages recently issued reports on CTEV. Piper Sandler reiterated an “overweight” rating and issued a $73.00 price target on shares of Claritev in a research note on Wednesday, August 12th. Canaccord Genuity Group boosted their target price on Claritev from $37.00 to $43.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Wells Fargo & Company increased their price target on Claritev from $22.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 12th. Citigroup reaffirmed a “buy” rating and set a $45.00 price target (up from $40.00) on shares of Claritev in a research report on Monday, August 10th. Finally, Wall Street Zen upgraded shares of Claritev from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $44.83.

Claritev Company Profile

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.